Evolus Inc
EOLSLatest QuantConomy context for EOLS: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.
Evolus Inc
Evolus Inc, traded under the symbol EOLS, is a performance beauty company focused on the cash-pay aesthetic market in the United States, Canada, and Europe. The company is renowned for its flagship product, Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation used to temporarily improve the appearance of moderate to severe glabellar lines in adults. In addition to Jeuveau, Evolus offers dermal filler products under the Estyme and Evolysse brands. Headquartered in Newport Beach, California, and founded in 2012, Evolus is committed to building a robust aesthetic portfolio supported by a customer-centric business model and innovative digital platforms.
- Symbol
- EOLS
- Name
- Evolus Inc
- Coverage
- 3 market/data records
- Sources
- fmp alphavantage alpaca sec nasdaq lse
Recent signals for EOLS
Scored rows are pulled from the same signal API used by the digests.
| Signal | Direction | Score | Observed | Reason |
|---|---|---|---|---|
| volume dry up | neutral | 17 | Jul 10, 04:31 PM | EOLS volume dry-up: 22% of expected volume for Friday 16:00 UTC, price flat 0.00% (strength 17) |
| signal cluster high activity | bearish | 55 | Jul 10, 04:30 PM | High activity cluster for EOLS: 4 signals across 3 types (TECHNICAL, VOLUME, PRICE) with mixed directions [moderate signal] |
| technical ma bearish cross | bearish | 63 | Jul 10, 04:02 PM | EOLS bearish MA crossover (9/21), strength 63 |
EARNINGS signals are experimental: currently limited to neutral pre-earnings calendar awareness (no transcript analysis).
TECHNICAL signals are experimental: realized 30-day directional accuracy is ~22% (short-horizon indicator moves tend to mean-revert). They are automatically down-weighted in composite scores but served raw here. Do not use them as standalone trade advice.
Market coverage
| Market | Exchange | Source | Asset record |
|---|---|---|---|
| EOLS | NASDAQ | fmp | Evolus, Inc. |
| EOLS | NASDAQ | alphavantage | Evolus Inc |
| EOLS | NASDAQ | alpaca | Evolus, Inc. Common Stock |
Recent insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Mar 20, 2026 | MOATAZEDI DAVID | See Remarks | sale | 13,669 | $4.75 | $64,929 | 4 on EDGAR |
| Mar 20, 2026 | Avelar Rui | See Remarks | sale | 3,119 | $4.75 | $14,815 | 4 on EDGAR |
| Mar 16, 2026 | MOATAZEDI DAVID | See Remarks | exercise | 67,489 | $0.00 | $0 | 4 on EDGAR |
| Mar 16, 2026 | Avelar Rui | See Remarks | exercise | 8,804 | $0.00 | $0 | 4 on EDGAR |
| Feb 17, 2026 | MOATAZEDI DAVID | See Remarks | grant | 313,212 | $0.00 | $0 | 4 on EDGAR |
| Feb 17, 2026 | Malik Vikram | Insider | grant | 45,559 | $0.00 | $0 | 4 on EDGAR |
| Feb 17, 2026 | Mitchell Tatjana | Chief Financial Officer | grant | 121,489 | $0.00 | $0 | 4 on EDGAR |
| Feb 17, 2026 | Stewart Brady | Insider | grant | 45,559 | $0.00 | $0 | 4 on EDGAR |
| Feb 17, 2026 | White Albert G III | Insider | grant | 45,559 | $0.00 | $0 | 4 on EDGAR |
| Feb 17, 2026 | Parschauer Karah Herdman | Insider | grant | 45,559 | $0.00 | $0 | 4 on EDGAR |
| Feb 17, 2026 | GILL DAVID N | Insider | grant | 45,559 | $0.00 | $0 | 4 on EDGAR |
| Feb 17, 2026 | Avelar Rui | See Remarks | grant | 94,913 | $0.00 | $0 | 4 on EDGAR |
| Dec 22, 2025 | MOATAZEDI DAVID | See Remarks | sale | 10,539 | $7.15 | $75,361 | 4 on EDGAR |
| Dec 22, 2025 | Avelar Rui | See Remarks | sale | 2,261 | $7.15 | $16,168 | 4 on EDGAR |
Source: SEC filings via QuantConomy. Not investment advice.
Query EOLS context like a database.
These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.
More: All insider trades · How to read a Form 4 · API access